Survival

NGM Bio Gives Presentation Featuring Preclinical Characterization of NGM936 at 2022 ASH Annual Meeting

Retrieved on: 
Tuesday, December 13, 2022
Necrosis, Associate, Liver, Health, SAN, Poster, NGM, Cancer, TNF, Multiple myeloma, ASH, CD34, AML, Indiana University School of Medicine, Gamma, Acute myeloid leukemia, IL-6, CD123, Survival, Retina, Research, Protein engineering, Disease, ILT3, Society, Ernest, Risk, TDCC, Biology, COVID-19, Patient, Therapy, Vaccine, Pharmaceutical industry

SOUTH SAN FRANCISCO, Calif., Dec. 12, 2022 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, provided additional detail today on the poster presentation given on the Company’s first disclosed preclinical bispecific program, NGM936, at the American Society of Hematology (ASH) Annual Meeting, which is taking place December 10 – 13, 2022 at the Ernest N. Morial Convention Center in New Orleans, Louisiana.

Key Points: 
  • Importantly, NGM936 efficiently ablated tumor cells with a range of ILT3 expression, from ~1500 copies/cell to ~40,000 copies/cell, in those studies.
  • NGM936 was discovered in-house by NGM Bio scientists.
  • NGM Bio will seek a partner for this program for clinical development in hematologic oncology indications.
  • All therapeutic candidates in the NGM Bio pipeline have been generated by its in-house discovery engine, always led by biology and motivated by unmet patient need.

New crash test spotlights lagging protection for rear passengers

Retrieved on: 
Tuesday, December 13, 2022
Eclipse, Honda, XC40, Head, Crash, Toyota, Volvo, Hyundai, Research, Insurance Institute for Highway Safety, Insurance, SD, Extremities, Chevrolet, HR-V, Mazda, Jeep Renegade (BU), Q3, Safety, Injury, Torso, Ford Escape, Hybrid, Audi Q3, FEC, Jeep Compass, Buick, Buick Encore, Mitsubishi, Neck, Education, Abdomen, CR, CX-5, RAV4, Nissan Rogue, Subaru, Survival, Equinox, Hertz, III, Ford Motor Company, Thigh, Forester, IIHS, Chest injury, Sport utility vehicle, Risk, Death, Child, Mitsubishi Eclipse Cross, Taxicab, Baggage, Medical device, Road, Poultry, Communications satellite, Encore, Escape, Renegade

“The original moderate overlap test was our first evaluation and the lynchpin of the Institute’s crash testing program,” said IIHS President David Harkey.

Key Points: 
  • “The original moderate overlap test was our first evaluation and the lynchpin of the Institute’s crash testing program,” said IIHS President David Harkey.
  • However, the additional measurements provided by the new test show that most of them don’t provide adequate protection for the rear passenger’s head and neck — the most vulnerable areas of the body.
  • Features like rear seat airbags and seat belts that themselves inflate to mitigate the effects of crash forces could help too.
  • The test speed, offset and barrier used in the new test remain the same as in the original one.

AB Science receives Notice of Deficiency (NOD) from Health Canada for masitinib in the treatment of amyotrophic lateral sclerosis (ALS)

Retrieved on: 
Tuesday, December 13, 2022
Euronext Paris, Cell, AMF, NOD, Medicine, Inflammation, Science, Marketing, Degenerative disease, Pengkhianatan G30S/PKI, Calendar, Amyotrophic lateral sclerosis, Tyrosine kinase inhibitor, Survival, AB, Research, NON, Euronext, Veterinary medicine, Health Canada, Pharmaceutical industry, Publishing, Deficiency

AB Science SA (Euronext - FR0010557264 - AB) today announced that it has received a Notice of Deficiency (“NOD”) for its masitinib New Drug Submission in the treatment of amyotrophic lateral sclerosis.

Key Points: 
  • AB Science SA (Euronext - FR0010557264 - AB) today announced that it has received a Notice of Deficiency (“NOD”) for its masitinib New Drug Submission in the treatment of amyotrophic lateral sclerosis.
  • This NOD means that Health Canada has requested the provision of additional information related to masitinib New Drug Submission.
  • The Response to a Notice of Deficiency is to be submitted within 90 calendar days from the date the NOD was sent.
  • AB Science will liaise with Health Canada to address the deficiencies, with the intention to resume the process within the allocated timeframe.

Biomea Fusion Presents at the 2022 ASH Annual Meeting Preclinical Data on BMF-500 Supporting its Potential as the Most Potent and Selective FLT3 Inhibitor to Date

Retrieved on: 
Monday, December 12, 2022
Society, Osteopathic medicine in Canada, RTK, FDA, Cancer, ASH, FLT3, U.S. Postal Service Pro Cycling Team, AML, Survival, Research, Human, IND, Standard of care, Mutation, Risk, Patient, Therapy, Pharmaceutical industry

“The majority of late-stage and approved FLT3 inhibitors fall short of providing sufficient and sustained inhibition of FLT3 signaling required for maximal benefit.

Key Points: 
  • “The majority of late-stage and approved FLT3 inhibitors fall short of providing sufficient and sustained inhibition of FLT3 signaling required for maximal benefit.
  • We believe that targeting FLT3 with a covalent inhibitor, as we did with menin, represents another significant opportunity to improve the outcomes that reversible inhibition provide.
  • Nearly 30% of AML patients have a FLT3 mutation, representing more than 6,000 incident patients in the United States each year.
  • Biomea Fusion explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.

New Avionics Innovation Helps Airlines Reduce 800 Tonnes of Co2 Emissions as WeSky Delivers the World's Lightest In-Seat Power Solution

Retrieved on: 
Monday, December 12, 2022
Electronics, USB, Carbon, Safety, Climate, COP27, Environment, Iran Aviation Industries Organization, Survival, Airbus, Research, Renewable energy, Airline, EU

The WeSky 60W USB Power Supply solution, recharge™️, is typically 70% lighter than existing equipment on the market.

Key Points: 
  • The WeSky 60W USB Power Supply solution, recharge™️, is typically 70% lighter than existing equipment on the market.
  • Other differentiations include increased flexibility and a faster delivery lead-time in light of current supply chain issues facing incumbent competitors.
  • WeSky hopes to lead in bringing new avionics products to the market that have climate and sustainability at its core.
  • Among many avionics innovations, WeSky develops a smart USB in-seat power solution called recharge™️ that allow commercial airlines to provide enhanced in-flight experiences and operating efficiency through lowering aircraft weight and fuel consumption.

Caribou Biosciences Selects ROR1 as the Target for CB-020, an iPSC-derived Allogeneic CAR-NK Cell Therapy

Retrieved on: 
Monday, December 12, 2022
Conference, RNA, B2M, NK, Rachel Haurwitz, CAR, Clinical trial, Annual report, Security (finance), Neoplasm, Growth hacking, DNA, Safety, Phenotype, Japanese Cancer Association, Risk, Reindeer, IPSC, Survival, Casitas, CRISPR/Cpf1, ROR1, Metastasis, Research, American Association for Cancer Research, CRISPR, Genome, Lymphatic system, CBLB, Patient, Therapy, Vaccine, Medical imaging, Paint, Sewing

BERKELEY, Calif., Dec. 12, 2022 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced target selection for CB-020, an induced pluripotent stem cell (iPSC)-derived allogeneic anti-ROR 1 (receptor tyrosine kinase like orphan receptor 1) CAR-NK cell therapy. Preclinical data on the selection of the CB-020 CAR construct and armoring strategies for Caribou’s CAR-NK cell platform will be presented today at the 12th American Association for Cancer Research and Japanese Cancer Association (AACR-JCA) Joint Conference.

Key Points: 
  • “We are leveraging our chRDNA genome-editing technology across our allogeneic CAR-T and CAR-NK cell programs to address disease-specific challenges.
  • ROR1 is a cell signaling receptor that is overexpressed on the surface of several solid tumor types and has been shown to drive tumor cell growth, survival, and metastasis.
  • Multiple armoring strategies are being developed for Caribou’s CAR-NK cell platform to enhance tumor targeting, allogeneic CAR-NK cell survival, and persistence of antitumor activity.
  • “Caribou Biosciences” and the Caribou logo are registered trademarks of Caribou Biosciences, Inc.

Mendus AB: Mendus presents positive survival data from the ADVANCE II trial evaluating DCP-001 as a maintenance therapy in AML at the American Society of Hematology (ASH) meeting

Retrieved on: 
Monday, December 12, 2022
CMO, Patient, Neoplasm, CET, Safety, Maintenance, ASH, Doctor of Philosophy, EU, Recurrence, AML, RFS, MD, Acute myeloid leukemia, Survival, MRD, Society, Minimal residual disease, Internet service provider, Pharmaceutical industry, Medical device, Vaccine, Mendu

ADVANCE II is a Phase 2 monotherapy trial evaluating DCP-001 as a maintenance therapy in acute myeloid leukemia (AML) for patients brought into complete remission through chemotherapy, but with measurable residual disease (MRD).

Key Points: 
  • ADVANCE II is a Phase 2 monotherapy trial evaluating DCP-001 as a maintenance therapy in acute myeloid leukemia (AML) for patients brought into complete remission through chemotherapy, but with measurable residual disease (MRD).
  • The ADVANCE II trial has completed the 70-week follow-up period after start of DCP-001 treatment, and patients are now in long-term follow up.
  • Median follow-up for the entire study population at the data cut-off for ASH on 22nd of November was 19.4 months.
  • The information was submitted for publication through the agency of the contact persons set out below on 12 December 2022, at 19:00 CET.

Kronos Bio Presents Preclinical Data Supporting Anti-Leukemic Activity of Lanraplenib in Combination with Multiple Targeted Agents in Acute Myeloid Leukemia (AML) Preclinical Models at American Society of Hematology Meeting

Retrieved on: 
Sunday, December 11, 2022
SYK, BCL2, CDK9, Bio, PDX, SAN, Lymphatic system, Security (finance), MLL, Cancer, Bone marrow, ASH, FLT3, CR, Acute leukemia, MYC, Survival, MRD, RT, KRON, Research, Chronic lymphocytic leukemia, Society, Apoptosis, Drug, Patient, Pharmaceutical industry, AML

SAN MATEO, Calif. and CAMBRIDGE, Mass., Dec. 11, 2022 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, is presenting preclinical data that demonstrate anti-leukemic activity of the investigational spleen tyrosine kinase (SYK) inhibitor, lanraplenib, in combination with multiple targeted agents in patient-derived cell isolates and cell lines at the 64th American Society of Hematology (ASH) Annual Meeting & Exposition in New Orleans. The data are being shared as part of a poster presentation.

Key Points: 
  • Lanraplenib is a next-generation SYK inhibitor that is currently being evaluated in combination with gilteritinib in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia (AML) in a Phase 1b/2 study.
  • The combination triggered differentiation and apoptosis, suggesting a more complete blockade of the HOXA9/MEIS1 transcriptional program through synergistic inhibition by orthogonal mechanisms.
  • Additionally, the researchers evaluated synergistic activity of lanraplenib with the FLT3 inhibitor, gilteritinib, and BCL2 inhibitor, venetoclax, in patient-derived AML isolates.
  • In a follow-up PDX study with an optimized regimen, the combination significantly extended overall survival compared to either single agent.

Vincerx Pharma Presents Preclinical Data on VIP943 in Acute Myeloid Leukemia Models at the 64th American Society of Hematology Annual Meeting 2022

Retrieved on: 
Sunday, December 11, 2022
Enzyme, Flow cytometry, WBC, Primate, ASH, AML, Hematocrit, Toxicity, COVID-19, Basophil, Observation, Bilirubin, Form 10-K, Gemstone, NHP, Reticulocyte, Safety, Cancer, Antibody-drug conjugate, CD123, Workforce, Biosimilar, Society, Pandemic, Hematology, Therapy, Diffusion, ADC, Control, Venetoclax, Male, PALO, Patient, Azacitidine, Failure, Bone marrow, Myelocyte, 8-K, Toxic shock syndrome, Drug Quality and Security Act, Survival, Lymphocyte, IND, KSPI, Fine chemical, Pharmaceutical industry, Risk management, Gemtuzumab ozogamicin, Bayer

PALO ALTO, Calif., Dec. 11, 2022 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today announced a poster presentation of preclinical data of Vincerx’s proprietary payload and linker technology and VIP943, the Company’s internalizing ADC targeting CD123, at the 64th American Society of Hematology (ASH) Annual Meeting 2022.

Key Points: 
  • VIP943 combines the unique payload class of kinesin spindle protein inhibitors (KSPi) with a proprietary legumain-cleavable linker.
  • “I am truly excited about the preclinical results for VIP943 and our proprietary payload and linker technology presented at ASH,” said Ahmed Hamdy, M.D., Chief Executive Officer of Vincerx.
  • The in vivo AML mouse model results also showed improved efficacy and survival for VIP943 in combination with venetoclax and azacitidine.
  • Forward-looking statements speak only as of the date hereof, and Vincerx disclaims any obligation to update any forward-looking statements.

Fate Therapeutics Highlights iPSC-derived, Off-the-shelf CAR NK Cell Programs for Multiple Myeloma at 2022 ASH Annual Meeting

Retrieved on: 
Saturday, December 10, 2022
Johnson & Johnson, Immunotherapy, Canadian Aviation Regulations, B-cell maturation antigen, CD16, BOR, Administration, Janssen, NK, CAR, PD, Cytokine release syndrome, Security (finance), SD, Neoplasm, Graft-versus-host disease, Antibody, AES, Safety, Cancer, Maintenance, Multiple myeloma, NA, Downregulation and upregulation, CD38, ASH, ADCC, IPSC, Neutropenia, CRS, GPRC5D, International Myeloma Foundation, DLT, Patient, Survival, Destiny, SAE, Research, Patent, Therapy, Antigen, Risk, Death, BCMA, Daratumumab, PR, Janssen Pharmaceuticals, Vaccine, Pharmaceutical industry, Fine chemical

SAN DIEGO, Dec. 10, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, today presented interim clinical data from the dose-escalation stage of its ongoing Phase 1 study of FT576 for patients with relapsed / refractory multiple myeloma (r/r MM) at the 64th American Society of Hematology Annual Meeting and Exposition. The off-the-shelf product candidate, which is derived from a clonal master engineered induced pluripotent stem cell (iPSC) line, incorporates a chimeric antigen receptor (CAR) targeting B-cell maturation antigen (BCMA) as well as a high-affinity, non-cleavable CD16 (hnCD16) Fc receptor to maximize antibody-dependent cellular cytotoxicity (ADCC) and enable dual-antigen targeting of myeloma cells through combination with monoclonal antibody (mAb) therapy. Preclinical data published last month in the journal Nature Communications (Cichocki et al. 2022, 13:7341) demonstrated that single-dose administration of FT576 was effective at controlling tumor growth in vivo, with deeper and more sustained anti-tumor activity observed through multi-dose administration of FT576 as well as in combination with the CD38-targeted monoclonal antibody daratumumab.

Key Points: 
  • Grade 3 or greater treatment-emergent AEs (TEAEs) not related to FT576 primarily included hematologic cytopenias associated with conditioning chemotherapy.
  • Administration of three doses of FT555 as monotherapy further improved tumor clearance and showed superior activity compared to single-dose primary CAR T cells.
  • Fate Therapeutics’ iPSC product platform is supported by an intellectual property portfolio of over 350 issued patents and 150 pending patent applications.
  • Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for patients with cancer.